Sex, Age, Race and Intervention Type in Clinical Studies of HIV Cure: A Systematic Review

Rowena E. Johnston¹ and Mary M. Heitzeg²

Abstract

This systematic review was undertaken to determine the extent to which adult subjects representing sex (female), race (nonwhite), and age (>50 years) categories are included in clinical studies of HIV curative interventions and thus, by extension, the potential for data to be analyzed that may shed light on the influence of such demographic variables on safety and/or efficacy. English-language publications retrieved from PubMed and from references of retrieved papers describing clinical studies of curative interventions were read and demographic, recruitment year, and intervention-type details were noted. Variables of interest included participation by sex, age, and race; changes in participation rates by recruitment year; and differences in participation by intervention type. Of 151 publications, 23% reported full demographic data of study enrollees, and only 6% reported conducting efficacy analyses by demographic variables. Included studies recruited participants from 1991 to 2011. No study conducted safety analyses by demographic variables. The representation of women, older people, and nonwhites did not reflect national or international burdens of HIV infection. Participation of demographic subgroups differed by intervention type and study location. Rates of participation of demographic groups of interest did not vary with time. Limited data suggest efficacy, particularly of early therapy initiation followed by treatment interruption, may vary by demographic variables, in this case sex. More data are needed to determine associations between demographic characteristics and safety/efficacy of curative interventions. Studies should be powered to conduct such analyses and cure-relevant measures should be standardized.

Introduction

EFFORTS TO “CURE” HIV—defined as either achieving a state in which the virus is controlled in the absence of medication (sometimes called “functional cure”) or the disabling or removal of all replication-competent virus (sometimes called “sterilizing cure”)—have been active since the 1990s. However, optimism for the potential to cure HIV has increased since the report¹ of the apparent cure of an HIV patient in Berlin after transplantation of stem cells homozygous for the CCR5 delta-32 mutation.

The limited number of cure cases to date makes it impossible to know which intervention(s) will prove most effective at curing HIV, or whether effectiveness will be equivalent across different groups of patients. Little is known about the potential for demographic factors to affect the safety or efficacy of curative interventions. Sex, age, or race may influence the establishment or persistence of reservoirs

of virus that are not targeted by antiretroviral treatment (ART) or the immune system, or efforts to disrupt them, via differences and fluctuations in hormones, X versus Y chromosome gene expression, HLA type, response to drugs [e.g., pharmacokinetic (PK) or pharmacodynamic (PD)], route of acquisition of infection, duration of infection before treatment initiation, immune activation/inflammation, and/or the presence of opportunistic and/or coinfections and morbidities, as outlined below.

Sex differences potentially related to cure

Clinical observations and studies have indicated that female sex is associated with lower viral load,^{2–6} higher CD4 count,^{6–8} more frequent ART side effects and discontinuation,^{9–18} faster progression to AIDS,^{4,19} higher D-dimer levels,²⁰ greater likelihood of elite control (Steven Deeks, personal communication), more pronounced immune and

¹amfAR, The Foundation for AIDS Research, New York, New York.

²Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.

vaccine responses,^{21–24} and higher immune activation.^{21,25–28} *In vitro* data, where ART exposure can be more easily controlled, also suggest possible effects of sex on measures of interest in curing HIV, including infection of and replication in cells, transcription, and HIV promoter activity.^{26,28–35} Biologically based sex differences, especially in immunity, may also arise from differential gene expression associated with the X chromosome,^{19,36–39} and sex differences may also be associated with access to or outcomes of bone marrow or hematopoietic stem cell transplantation (HCT).^{40–45}

Evidence suggests that a smaller persistent viral reservoir may be associated with longer time to rebound after therapy interruption.^{1,46,47} Factors determining the size of the reservoir may include duration of infection before ART initiation⁴⁸ or CD4 nadir.⁴⁹ In addition to biological differences between males and females, sociobehavioral factors (such as access to care or level and duration of viral suppression) may also affect these variables and thus the safety or efficacy of curative interventions. A 2009 publication reported that in Europe women were more likely to receive ART than men.⁵⁰ A recent WHO/UNAIDS update extended this finding, by reporting that globally, women are more likely than men to be accessing ART,⁵¹ likely due largely to increased ART uptake in antenatal care clinics. Recent data issued by the U.S. national government on the HIV continuum of care confirm that while women have slightly higher rates than men of new HIV diagnoses and linkage to care, women and men are equivalent in terms of viral suppression.⁵²

Age differences potentially related to cure

Clinical observations indicate that older age is associated with shorter time to death, smaller CD4 increase on ART, lower viral load but faster viral load increase off ART, altered PK, and increased immune activation.^{53–61} Older patients may also have a decreased ability to mount immune responses against the virus.^{62–67} Age differences are strongly associated with access to or outcomes of HCT.^{42,68–72}

Sociobehavioral factors may also be important for age. Older adults in North America are likely to present for care at lower CD4 counts than younger adults,⁷³ and the same is true in Europe.^{74,75} According to U.S. continuum of care data, linkage to care is lowest in young adults, but rates of viral suppression in those aged 65 years and older compare unfavorably to rates in those aged 45–64 years.⁵²

Race differences potentially related to cure

In the context of HIV, race has been associated with differences in plasma viral load,^{76,77} CD4 count,^{6,76} rate of CD4 decline,⁷⁸ D-dimer levels,²⁰ HLA-associated vaccine response or viral escape,^{79,80} disease progression and death,⁸¹ immune and vaccine responses,^{82,83} and increased systemic immune activation.^{84–86} Associations between race and the function of enzymes involved in the metabolism of drugs, including ART, have also been described.^{87–91} Although HLA-B*5701 may be a better predictor of abacavir sensitivity than race,⁹² a study in the United Kingdom demonstrated a substantially lower prevalence of the B*5701 HLA type in Africans compared to whites.⁹³ Race differences in pharmacodynamics have also been noted for responses to therapeutic interferon- α in HIV/hepatitis C-coinfected subjects.⁹⁴ Results from the VaxGen trial indicated that blacks

and Asians generated higher levels of antibodies against HIV than other participants.⁹⁵

As with sex, race differences may also be associated with access to or outcomes of bone marrow or HCT. African Americans are less likely than whites to undergo HCT.⁴⁰ In a retrospective analysis of more than 3,000 patients who received HCT between 1992 and 2000, black was the only race associated with significantly higher mortality and graft-versus-host disease (GVHD) than whites.⁹⁶

Sociobehavioral differences between races have also been observed. In this context, differences between races considered “majority”—either numerically or, more importantly, according to socioeconomic advantage—versus “minority/other” are of particular interest. In Europe, those not of European origin were more likely to present for care later.^{73,74} At all points along the HIV continuum of care in the United States—particularly in new diagnoses, engagement in care, and suppression of viral load—blacks are doing more poorly than other races.⁵²

Demographic predictors in hepatitis C cure

The only viral disease for which a medical “cure” (more commonly referred to as sustained virological response, SVR) is regularly attained is hepatitis C virus (HCV). Some evidence indicates that demographic characteristics might be associated with variable rates of SVR in HCV. A recent report described treatment outcomes in older (60 years or above) versus younger patients treated with peginterferon alpha-2a and ribavirin. Patients in the older group had to stop treatment more often due to virological failure and adverse events, and were significantly less likely to reach SVR, despite higher compliance and less loss to follow-up.⁹⁷ Malnick *et al.* (2014) reviewed several clinical trials of various HCV treatments and found that those aged 65 years or older were often excluded from trials, but where data were available, older patients discontinued treatment at a higher rate and/or achieved SVR at a lower rate than younger study participants.⁹⁸

Narciso-Schiavon *et al.* (2010) reported that although women had more adverse events than men, SVR rates were similar between the sexes.⁹⁹ In those receiving liver transplants and experiencing HCV recurrence, SVR rates in genotype 1 patients were lower in women than men.¹⁰⁰ More recently, the use of sofosbuvir has improved SVR rates. In the NEUTRINO and FISSION studies, age (above or below 50 years) predicted SVR rates with different treatment combinations, and while male sex and black race appeared to be associated with lower SVR, these differences were not significant.¹⁰¹

Study objectives

The National Institutes of Health (NIH), the world’s largest single funder of clinical research, has recognized the importance of including representatives of diverse demographics in clinical studies and requires investigators to include and examine differential effects by sex and diverse racial and ethnic groups in studies conducted with human subjects or on material of human origin such as tissues or specimens.¹⁰² More recently, they have issued a policy requiring researchers to balance female and male animals and cells in preclinical research studies.¹⁰³

Although sex, age, and race are associated with measures thought to be important in curing HIV, via biological and/or sociobehavioral effects, it is currently unknown whether these demographic factors are associated with the safety or efficacy of any curative intervention. This systematic review was undertaken to determine the extent to which adult subjects representing different sex, race, and age categories are included in clinical studies of curative interventions and thus, by extension, the potential for data to be analyzed that may shed light on the influence of such demographic factors on safety and/or efficacy.

Materials and Methods

Search methodology

Clinical intervention studies for which adult males and females were eligible, published through the end of 2013, whose ultimate goal was to inform efforts to cure HIV either by enhancing control of HIV in the absence of ART (i.e., “functional cure” or “remission”) and/or perturbing the persistent viral reservoir by disabling, reducing, or removing replication-competent virus (i.e., “sterilizing cure” or “eradication”), were included.

PubMed was used to search for relevant English language publications, and the references of retrieved papers were also scanned. Publications were included if they involved at least one post hoc analysis of a measure pertinent to curing HIV (e.g., reservoir size) even if other publications referring to the same study stated that the original intent of the study was not cure related. To maximize the number of studies, all clinical studies, not just those that were randomized and/or blinded and/or controlled, were included. Case studies of single patients were not included, nor were conference abstracts. Similarly, explicitly pediatric studies were excluded, but the inclusion criteria of some included studies involved participants aged 13 years or older. One publication per study was included in the analysis. When more than one publication referred to a single study, the publication judged to have the most complete demographic data was used.

Variables

Various demographic and other data were collected from each of the analyzed publications. The total number of participants included or enrolled into the study was noted, without regard to whether participants received any or all of the intended interventions or whether they were included in analyses, as the main measure of interest for this systematic review was to assess the access or willingness to participate, and/or the willingness/ability of researchers to recruit, participants who are female, older, or nonwhite. Where data were available, the numbers of women (including male-to-female transgender), “older” (defined as 50 years or over), and nonwhite participants included were noted. Reported analyses of safety or efficacy differences in the three demographic variables of interest were also noted.

The year in which the study started recruiting was judged to be a more accurate indication of the timing of the study than the year of publication because of potential variations in time to publication. Where data were not available in the publication, data on recruitment period were gathered on the basis of NCT numbers (or other publications describing

the same study), when available. The country(ies) in which the studies took place were also noted.

Cure interventions

Cure interventions were classified according to seven categories: ATI, cell therapy, early treatment, immune modulation, intensification, reactivation, and therapeutic vaccine. ATI included studies in which ART was interrupted as an intervention (i.e., to enhance the likelihood of viral control in the absence of ART by, e.g., boosting immune responses), or when it was used as a measure of the success of the intervention. Treatment interruption studies in which the stated goal was to save cost or minimize toxicities, etc. were not included. Cell therapy included studies of gene therapy and/or cell transplantation. Early treatment involved the initiation of ART during a time period classified by study authors as early in infection. Immune modulation included interventions thought to enhance the function of the immune system independently of classic vaccine responses, including agents that affect the number or function of CD4, CD8, or other immune cells. Intensification was defined as the addition of ART agents beyond standard medical practice. Reactivation studies employed agents such as histone deacetylase inhibitors (and other drug classes) aimed at increasing transcription from proviral DNA. Therapeutic vaccine studies employed vaccines aimed at stimulating the host immune system to generate more effective cellular and/or humoral control of existing infection. Single studies that included more than one category of intervention were assigned to each of the categories described in the study.

Statistical analyses

Statistical analyses were performed using SPSS (Version 19.0, IBM Corp., Armonk, NY). Trends across time and differences across interventions were investigated using a general linear model (GLM). Linear regression was used to determine trends across time, with recruitment year (1991–2008) coded as a continuous variable, beginning at zero (year 1991). Linear models were fit to enable detection of increasing or decreasing trends and quadratic models (which included the linear term) were fit to detect curvilinear trends. To determine differences across interventions, one-way analyses of variance (ANOVA) were used with intervention type as the independent variable. The remaining analyses were conducted using nonparametric tests. To determine differences in sex and nonwhite participation in interventions, one-sample binomial *z*-tests were conducted using the proportion of total subjects per intervention as the expected value and proportion of women or nonwhites as the observed value. Differences across countries were investigated with Pearson Chi-square tests. For comparisons across the seven interventions, type I error was controlled using a Bonferroni-corrected threshold to establish significance ($0.05/7=0.007$). For all other comparisons, significance was established at $\alpha < 0.05$.

Results

General

In all, 151 publications were retrieved describing 159 studies that were judged nonduplicative. (Six publications described two studies and one publication described three

studies.) Studies were published between 1995 and 2013. Recruitment periods were available for 76 publications, with start dates ranging from 1991 to 2011. Time from start of recruitment to publication ranged from 0 to 13 years (mean 5.7, median 5). The 159 studies included a total of 14,345 participants. The number of participants per study ranged from 2 to 4,111 (mean 94, median 25). Each study included 1–3 (mean 1.3, median 1) interventions (e.g., patients were treated early in infection, then administered a therapeutic vaccine, followed by a treatment interruption).

The 137 studies conducted within single countries took place in Argentina (1), Australia (4), Belgium (2), Brazil (2), Canada (4), Denmark (1), France (16), Germany (6), Hungary (1), Italy (5), Japan (1), Netherlands (4), Norway (1), Spain (11), Sweden (4), Switzerland (1), Thailand (2), United Kingdom (4), and the United States (67). Table 1 provides an overview of publications and studies by intervention, demographics, and number of study countries.

Interventions

Of the 14,345 participants in clinical studies, fewer than 1% joined reactivation studies, whereas over 50% were included in immune modification studies. More data are shown in Table 2. While the average number of participants in each type of intervention varied widely (Fig. 1), a one-way ANOVA found that differences across all seven intervention types were not significant ($F_{6,198} = 1.0, p = 0.403$). This is likely due to broad intraindividual variability.

In terms of the number of participants, Intensification ($R^2 = 0.277, df = 1,16, p = 0.025$) and Tx vaccine ($R^2 = 0.237, df = 1,16, p = 0.041$) showed linear increases from 1991 to 2008, whereas ATI ($R^2 = 0.552, df = 2,15, p = 0.002$) and Immune Mod ($R^2 = 0.403, df = 2,15, p = 0.021$) showed quadratic trajectories. However, only the trajectory for ATI passed threshold for multiple comparisons ($\alpha = 0.007$).

Studies of Early tx, Cell tx, and Reactivation interventions did not change over time ($ps > 0.21$). To visualize these effects,

TABLE 1. OVERVIEW OF PUBLICATIONS AND STUDIES BY DEMOGRAPHICS, INTERVENTION TYPE, AND STUDY COUNTRIES

	Number of publications (of 151)	% publications	Number of studies (of 159) ^a	% studies
Intervention ^b				
Early treatment	34	22.5	37	23.3
Cell therapy	17	11.3	17	10.7
Immune modification	38	25.2	42	26.4
Treatment intensification	18	11.9	19	11.9
Reactivation	6	4.0	6	3.8
Treatment interruption ^c	51	33.8	54	34.0
Therapeutic vaccine	40	26.5	41	25.8
Demographics				
Women				
Insufficient data	32	21.2	34	21.4
None	32	21.2	32	20.1
At least 1 participant	87	57.6	93	58.5
Older ^d				
Insufficient data	56	37.1	61	38.4
None	21	13.9	21	13.2
At least 1 participant	74	49.0	77	48.4
Nonwhite				
Insufficient data	105	69.5	112	70.4
None	4	2.6	4	2.5
At least 1 participant	42	27.8	43	27.0
Number of demographic variables reported ^e				
0	25	16.6	27	17.0
1	27	17.9	29	18.2
2	64	42.4	68	42.8
3	35	23.2	35	22.0
Study country				
Single	133	88.1	137	86.2
Multiple	14	9.3	16	10.1
No data	4	2.6	6	3.8

^aNumber of studies is greater than number of publications because six publications reported on two studies and one publication reported on three studies.

^bInterventions do not add up to total numbers of publications and studies because many publications and studies included more than one type of study.

^cIncluded studies where treatment interruption was an intervention or was used to evaluate success of an intervention.

^dDefined as 50+ years of age.

^eAmong: number of women; whether included participants 50+ years old; number of nonwhite race.

TABLE 2. PARTICIPANTS PER INTERVENTION TYPE

<i>Intervention type</i>	<i>Number of participants</i>	<i>Median number of participants</i>	<i>Median number of women (number of studies missing data)</i>	<i>Median number of nonwhite (number of studies missing data)</i>
Early treatment	3,285	34	5 (5)	8 (23)
Cell therapy	245	8	0 (5)	4 (9)
Immune modulation	7,516	30	5 (10)	7 (30)
Treatment intensification	394	13	1 (2)	13 (14)
Reactivation	113	11	3 (1)	n/a (6)
Treatment interruption	4,566	40	7 (9)	14 (36)
Therapeutic vaccine	2,381	36	3 (8)	5 (24)

years were divided into three epochs: pre-cART (up to and including 1995), triple cART (1996–2002), and multi-cART (2003–2008). A fourth epoch, post-Berlin patient (2009–present), was not included in analyses as there were too few studies retrieved (consistent with the observation that the mean time from recruitment to publishing was 5.7 years). As Fig. 2 illustrates, recruitment into ATI and Immune Mod intervention studies peaked during the triple-cART epoch, whereas recruitment into Intensification and Tx vaccine studies continued to increase over epochs into the multi-cART epoch.

Demographics—general

Of 151 publications, 23% provided some detail of the demographics of participants on all three measures—sex, inclusion of older participants, and race; 42% of publications provided details on two demographic variables, 18% provided details on one demographic variable, and the remaining 17% of publications provided no demographic details (see Table 1). No study reported conducting analyses of safety/adverse event outcomes by any of the demographic variables investigated in this systematic review. There were no significant differences in the number of demographic variables reported across intervention types ($F_{6,190}=0.8$, $p=0.609$), nor were there linear ($R^2=0.158$, $df=1,16$, $p=0.102$) or quadratic ($R^2=0.163$, $df=2,15$, $p=0.264$) changes across the timeframe of 1991 to 2008.

FIG. 1. Mean number of participants in each type of intervention. Error bars indicate ± 1 standard error.

Sex

Data on the sex of participants were available in 119 (79%) of 151 publications, 125 of 159 (79%) studies. Of the 12,946 participants in those studies, 2,323 (17.9%) were women. The percentage of women in the studies ranged from 0 to 89% (mean 14%, median 11%). Of the 125 studies where sex data were available, 32 (26%) reported no women in the study. A total of 140 publications described studies conducted entirely within ($n=65$) or entirely outside ($n=75$) the United States. There was a trend for publications reporting zero women, or where the number of women was not reported, to be conducted in the United States ($\chi^2=3.2$, $p=0.075$; United States 34/65, outside 28/75; Fig. 3).

Of the 2,323 women included in studies, fewer than 1% participated in cell therapy or reactivation studies. More than 50% of all female participants took part in studies of immune modulation. Compared with all participants, women were less likely to take part in Early tx ($z=4.85$, $p<0.001$), Cell tx ($z=3.76$, $p<0.001$), Intensification ($z=4.48$, $p<0.001$), and

FIG. 2. Number of studies of each intervention type by epoch. The recruitment year variable was divided into four epochs: pre-combination antiretroviral therapy (cART) (up to and including 1995), triple cART (1996–2002), multi-cART (2003–2008), and post-Berlin patient (2009–present). The most recent epoch was not included in this analysis as there were too few studies included in this review. * $p<0.05$, ** $p<0.007$.

FIG. 3. Participation of women and nonwhites in studies conducted entirely within or outside the United States. ⁺ $p < 0.08$, ^{**} $p < 0.001$.

Tx vaccine ($z = 5.23$, $p < 0.001$) interventions and were more likely to be in Immune mod ($z = 3.53$, $p < 0.001$) and ATI ($z = 5.82$, $p < 0.001$) interventions. All survive correction for multiple comparisons ($\alpha = 0.007$). There was no difference for Reactivation ($z = 1.04$, $p = 0.298$) intervention studies (Fig. 4).

As a median percentage of all participants in each intervention type, studies of immune modulation and reactivation recruited the greatest number of women, while cell therapy studies recruited the fewest. There were no significant differences in percentage of woman participants across intervention type ($F_{6,158} = 1.1$, $p = 0.356$, Fig. 5A). However,

FIG. 4. Sex differences in participation by intervention. One-sample binomial z -tests were conducted using the proportion of total subjects per intervention as the expected value (black bars) and proportion of women as the observed value (gray bars). Proportions are represented as percentages. ^{**} $p < 0.007$.

B

	Cell tx	Immune Mod	Intens	React	ATI	Tx Vaccine
Early tx	.087	.187	.254	.368	.317	.649
Cell tx		.010*	.276	.211	.032*	.126
Immune Mod			.007**	.848	.766	.521
Intensification				.316	.013*	.238
Reactivation					.750	.652
ATI						.681

FIG. 5. (A) Mean percentage of women recruited into each type of intervention. Error bars indicate ± 1 standard error. Lines indicate significant (at $p < 0.05$) differences between interventions from pairwise t -tests. (B) p -values of pairwise t -tests showing differences between interventions in the mean percentage of women participants. * $p < 0.05$, ^{**} $p < 0.007$.

exploratory independent sample t -tests show differences between intervention types (Fig. 5B). More data are shown in Table 2.

There were no significant linear ($R^2 = 0.050$, $df = 1,16$, $p = 0.372$) or quadratic ($R^2 = 0.171$, $df = 2,15$, $p = 0.245$) changes in percentage of women participants from 1991 to 2008.

In all, 87 (57.6%) publications reported including at least one woman. Of these, seven (8%) reported conducting sex difference analyses, of which two reported that there were significant sex differences in efficacy outcomes.

Age

Data on the inclusion of participants aged 50 years or older were available in 95 (63%) of 151 publications, 98 (62%) of 159 studies. The number of older participants was available for only 45 publications and studies. Of these, 21 publications and studies reported no older participants. The percentage of older participants ranged from 0 to 60 (mean 13.4, median 8.3). A total of 49 publications (52 studies) reported that participants aged 50 years or older were included, but not how many. Six publications (seven studies) reported conducting age difference analyses, and no differences were found.

Because only 24 publications and studies reported the number of older participants ($n = 72$), no further analyses were conducted on this variable.

Race

Data on the number of nonwhite participants included in studies were available in 46 (30%) of 151 publications, 47 of 159 (30%) studies. Of the 8,074 participants in those studies, 1,904 (23.6%) were nonwhite. The percentage of nonwhites in studies ranged from 0 to 60% (mean 25.5%, median 23%). Of the 47 studies where nonwhite data were available, four (8.5%) reported no nonwhites in the study. A total of 140 publications described studies conducted entirely within ($n=65$) or entirely outside ($n=75$) the United States. Publications reporting zero nonwhites, or where the number of nonwhites was not reported, were less likely to be conducted in the United States than outside the United States ($\chi^2=12.7$, $p<0.001$; United States 38/65, outside 64/75; Fig. 3).

Of the 1,904 nonwhite participants included in studies, none was included in reactivation studies, while more than 70% took part in studies of immune modulation. Compared with all participants, nonwhites were less likely to take part in Early tx ($z=9.32$, $p<0.001$), ATI ($z=9.98$, $p<0.001$), and Tx vaccine ($z=7.27$, $p<0.001$) and more likely to be in Cell tx ($z=2.85$, $p=0.004$) and Immune mod ($z=20.45$, $p<0.001$) intervention studies (Fig. 6). All survive correction for multiple comparisons ($\alpha=0.007$). There was no difference for Intensification ($z=0.44$, $p=0.660$).

As a median percentage of all participants in each intervention type, studies of treatment intensification and treatment interruption recruited the greatest number of nonwhite participants, while reactivation studies recruited none. Among the six intervention types that did recruit nonwhite participants, there were no significant differences in the percentage of nonwhite participants across intervention type ($F_{5,57}=0.2$, $p=0.943$; Fig. 7). Furthermore, exploratory independent sample t -tests did not reveal differences between intervention types ($ps>0.21$). More data are shown in Table 2. Included in these data are two studies (one Early tx and one Tx Vaccine) that had 100% nonwhite participants: one was conducted in Thailand and the other in Japan (in which all

FIG. 6. Race differences in participation by intervention. One-sample binomial z -tests were conducted using the proportion of total subjects per intervention as the expected value (black bars) and proportion of nonwhites as the observed value (gray bars). Proportions are represented as percentages. ** $p<0.007$.

FIG. 7. Mean percentage of nonwhites recruited into each type of intervention. Error bars indicate ± 1 standard error. No nonwhites were reported as participants in reactivation interventions. Pairwise t -tests revealed no significant differences between interventions.

subjects were either Thai or Japanese, respectively). Because the aim of this review was to identify the rate at which subjects considered “minority” are recruited into studies, we conducted the analyses without these studies and the results did not change (ANOVA: $F_{5,55}=0.9$, $p=0.497$; t -tests: $ps>0.24$).

There were no significant linear ($R^2=0.051$, $df=1,14$, $p=0.403$) or quadratic ($R^2=0.180$, $df=2,13$, $p=0.276$) changes in percentage of nonwhite participants from 1991 to 2008. Two (1.3%) publications/three (1.9%) studies reported conducting race difference analyses, and no differences were found.

Although it would have been interesting to conduct an interaction analysis to test whether combinations of demographic characteristics were associated with any of the variables of interest, almost no publications provided demographic data in sufficient detail to allow such an analysis.

Discussion

Recruitment into clinical studies

Of adults living with HIV in the United States in 2010, 33% were female, 67% were nonwhite,¹⁰⁴ and 19% were older than 55 years.¹⁰⁵ Worldwide, women account for 50% of all those living with HIV,¹⁰⁶ older adults constitute 10%,¹⁰⁷ and 85% are living in regions of the world where white is not the predominant race.¹⁰⁸ Despite the populations in which HIV infection is prevalent, and funder policies requiring representative participation in clinical studies,¹⁰² this systematic review suggests that participation in cure studies does not accurately reflect national or international burdens of infection in women, older adults, or nonwhites.

If the safety and efficacy profiles of curative interventions were known to be equivalent across different demographic groups, it may not be as important that studies are conducted largely in young white males. However, this systematic review reveals that the current data are insufficient to draw this conclusion. It is currently believed that an HIV cure may initially be more feasible in those whose virus is well

suppressed. In the United States, this tends to be found more often in whites, equally in males and females, and more often in those aged 55–64 years.⁵² The GRACE (gender, race, and clinical experience) trial demonstrated that it is possible to recruit women and racial minorities into HIV clinical research.¹⁰⁹ At this relatively preliminary time in the development of curative strategies, it will be crucial to determine if differences associated with demographics exist.

Are there demographic differences?

Although many data points were missing in the current review, making broader generalizations difficult, some interesting observations emerged. Two publications noted sex differences in intervention efficacy, and both were studies of early treatment followed by treatment interruption. Desquilbet *et al.* (2004) described 58 patients, including 13 women, in the French PRIMO cohort who started therapy during acute (none or one Western blot band) or early (two or more Western blot bands) infection. There was a median 1.5 years of viral suppression before patients elected to stop therapy for various reasons. At 12 months postinterruption, women had significantly lower viral loads (by a log) than men. As previously described in other studies, women also had lower baseline viral loads, but even when adjusted for baseline viral load, women still had lower off-therapy viral loads.¹¹⁰ Hoen *et al.* (2005) conducted the PRIMSTOP study, also in France, in 26 patients (five women) who initiated ART (plus hydroxyurea) for 34 weeks during primary infection (three or fewer Western blot bands), followed by alternating periods of treatment interruption and ART. In a multivariate analysis, female sex was the only variable that predicted virological success (defined as VL < 1,000) 6 months after ART discontinuation. Virological success was also associated with greater gains in CD4 T cells. As in other studies, these authors noted that women also started with lower baseline viral loads.¹¹¹

Replicating these studies of early treatment in women in other settings may prove challenging. It is commonly believed that women are rarely diagnosed and treated during early infection, although national data confirming this appear to be lacking. However, data from cohorts and studies indicate that such women are in fact available. Data from the Duke-UNC Acute HIV Infection Research Consortium indicate that 12% of the cohort is female,¹¹² somewhat lower than the 22% of HIV cases in females in North Carolina in 2012.¹¹³ Similarly, the primary infection Options cohort in San Francisco consists of about 4% women,¹¹⁴ reflecting the low contribution (about 8%¹¹⁵) of women to that city's epidemic. However, a 2006 publication¹¹⁶ reported that 33% of patients who enrolled in the Acute Infection and Early Disease Research Program (AIEDRP) at the site in Baltimore, Maryland were female, close to the 35% of all HIV cases in Baltimore in 2014.¹¹⁷ In France, in the PRIMO cohort consisting of 1,267 patients enrolled during primary HIV infection, 16% were women,¹¹⁸ lower than the national 29% of all HIV cases.¹¹⁹ Although not necessarily reflective of national averages, the SPARTAC trial conducted across eight countries (United Kingdom, South Africa, Brazil, Uganda, Spain, Australia, Italy, and Ireland) consisted of a cohort of 371 subjects identified during primary infection, of whom 40% were women.¹²⁰

It is possible that some combination of demographic variables may also have been associated with participation or efficacy. For example, it may be possible that a certain intervention is more efficacious in black females, or that older males are more or less likely to participate in studies than other subjects. Study subjects can be described by, and embody the characteristics of, multiple demographic and other descriptors. Data available in the publications described in this review did not often enough provide the level of detail that would be required to conduct such analyses.

Factors associated with participation of underrepresented groups

Historically, women, older people, and nonwhites have been underrepresented in HIV clinical studies^{121–123} and many reasons for this have been invoked, ranging from medical mistrust to poverty to childcare and employment challenges.^{124–126} In addition, care provider attitudes toward and perceptions of female, older, and nonwhite patients also tend to be more negative,^{127–129} which may negatively influence the likelihood of solicitation into clinical research. Taking these factors together, it is perhaps not surprising that women, older people, and nonwhites are underrepresented in HIV cure-related clinical studies. Despite NIH guidelines, there was a tendency for publications reporting zero female participants, or where the number of women was not reported, to be conducted more often inside than outside the United States. However, studies including nonwhites were significantly more likely to take place inside the United States than outside. The participation of these two groups in clinical studies of cure interventions has not changed in the period 1991–2008.

It should be noted that it is conceivable that some studies may be relevant only to circumscribed populations. In an attempt to correct for this bias, this study undertook to review only those studies for which both men and women were eligible. However, there may be limitations, such as CCR5 genotype, that might guide the exclusion of some types of patients, especially nonwhites, in whom the delta-32 allele would not be expected to be present.¹³⁰

It is interesting to note that women and nonwhites are more and/or less likely than participants overall to take part in certain types of cure studies. Women and nonwhites were both more likely to take part in immune modulation studies when compared to all participants. It is difficult to know whether such studies are more appealing to these participants or if so, why. From the opposite perspective, immune modulation and reactivation studies had a greater percentage of women included than other types of studies, while studies of treatment intensification and treatment interruption recruited more nonwhites than did other types of studies. Again, it is difficult to understand the differences in the motivations or behaviors of the researchers recruiting participants to these studies.

It is possible to speculate that physicians or health care providers serving as a link between these populations and different types of cure studies may make assumptions about health literacy or self-efficacy associated with sex or race and that these assumptions may either guide the ways in which they present studies to potential participants (leading to differences in the appeal of various kinds of studies) or the

extent/range of efforts they employ to recruit such participants (leading to differences in percentage participation). For reasons that would be more difficult to understand, there may also be systematic differences between study types in methods or locations of advertising and recruitment efforts (e.g., inner city clinics versus college campuses). There was no apparent relationship between the geographic location of particular study types, either between or within countries, and the likelihood of inclusion of women or nonwhites.

Potential to generate data on demographics

Despite the general paucity of analyses by demographics in this dataset, it may nonetheless be possible—with access to the raw data—to conduct post hoc analyses (or meta-analyses), even if only descriptive (especially in those studies with insufficient participant numbers to conduct formal analyses). Many of the studies in this dataset anecdotally described unusual safety or efficacy outcomes, but rarely provided demographic data of those participants. It is remarkable that no studies conducted analyses by demographics on safety outcomes.

Analyses of biomedical outcomes according to demographic variables can be challenging to interpret. Sex, although arguably the most clear-cut of the three demographic variables investigated here because of its categorical nature, can be complicated by age (e.g., premenopausal versus postmenopausal) and/or the use of hormonal contraceptives. For this systematic review, 50 years of age was chosen as a cut-off for “older” participants, to mirror many epidemiological reports. However, age is a continuous variable with no major biological differences expected in relevant measures in individuals close to the cut-off on each side. Age may also have very different associations with outcomes depending on whether the participant acquired HIV at a younger age and has aged with the virus, or whether the virus was acquired in older age. Race is potentially the most complicated of these variables. For these analyses, white vs. nonwhite was chosen as the comparator, but there is little a priori reason not to choose some other category demarcation, for example, black vs. nonblack. In fact, more genetic variation among blacks has been reported than among all other races,¹³¹ so the latter analysis may have more biological relevance.

In the context of biomedical HIV research, HLA may be better related to safety and/or efficacy than race, especially for interventions that require an immune response associated with particular HLA types. However, reporting the race of participants would still provide a useful indicator of the access to or willingness to participate in cure studies. To conduct such analyses, participants representing each of these demographics will need to be recruited to studies in adequate numbers. Investigators interested in probing the associations between demographic variables and safety or efficacy will face many challenges.

Limitations

Although steps were taken to identify duplicates, we cannot rule out the possibility that some publications described studies that were at least partially overlapping with others, and as such some participant groups may be overrepresented. There may also be other publications describing studies that fit the inclusion criteria that we did not identify, possibly

resulting in underrepresentation of other participant groups. In addition, it is possible that in cases where single studies were described in multiple publications, the publications not included in this systematic review may have included demographic analyses that were not identified, although efforts were made to minimize this. Finally, identifying clinical studies that fit the stated cure definition was in many cases a judgment call, and others may have classified the included and excluded publications differently.

One of the greatest limitations of this systematic review was the lack of data concerning some key variables. Data on the number of women, older people, and nonwhites were missing for 21%, 84%, and 70% of publications, respectively, limiting our ability to analyze the associations between these variables and participation in studies of different interventions over time. In some studies where these demographics were reported, no participants in those categories were included, further limiting the analysis. In addition, the year in which recruitment started was available for only 50% of publications. Despite these limitations, significant differences were still found on a number of measures. It is not possible to know whether the results reported in this systematic review would change if these data were available.

Recommendations

Several recommendations emerge from this study: (1) study authors should report at least basic (sex, age, race) demographic data of those who enroll into studies and those whose data are analyzed; (2) outcomes—both safety and efficacy—should be analyzed by demographic variables and results of such analyses should be reported; (3) to the extent possible, studies should be powered to explore demographic differences; (4) when studies are not sufficiently powered to allow such analyses, meta-analyses among similar interventions may provide important information; (5) to facilitate such meta-analyses, standardized endpoint measures should be taken, including, for example, changes in viral load, CD4 count, and proviral DNA, at a minimum; and (6) animal studies may provide preliminary indications of potential demographic differences, at least concerning sex and age.

Acknowledgments

The authors would like to thank Shirin Heidari, Samuela Rossi, Mirjam Cuomo, Matt Price, and Ioannis Hodges-Mameletzis for thoughtful discussion on the participation of women in HIV research. The authors also thank Jeffrey Laurence and Greg Millett for feedback on an earlier version of this article.

Author Disclosure Statement

No competing financial interests exist.

References

1. Hutter G, Nowak D, Mossner M, *et al.*: Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. *N Engl J Med* 2009;360(7):692–698.
2. Sterling TR, Vlahov D, Astemborski J, *et al.*: Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. *N Engl J Med* 2001;344(10):720–725.

3. Napravnik S, Poole C, Thomas JC, *et al.*: Gender difference in HIV RNA levels: A meta-analysis of published studies. *J Acquir Immune Defic Syndr* 2002;31(1):11–19.
4. Farzadegan H, Hoover DR, Astemborski J, *et al.*: Sex differences in HIV-1 viral load and progression to AIDS. *Lancet* 1998;352(9139):1510–1514.
5. Gandhi M, Bacchetti P, Miotti P, *et al.*: Does patient sex affect human immunodeficiency virus levels? *Clin Infect Dis* 2002;35(3):313–322.
6. Meditz AL, MaWhinney S, Allshouse A, *et al.*: Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. *J Infect Dis* 2011;203(4):442–451.
7. Delmas MC, Jadand C, De Vincenzi I, *et al.*: Gender difference in CD4+ cell counts persist after HIV-1 infection. SEROCO Study Group. *AIDS* 1997;11(8):1071–1073.
8. Prins M, Robertson JR, Brettle RP, *et al.*: Do gender differences in CD4 cell counts matter? *AIDS* 1999;13(17):2361–2364.
9. Currier JS, Spino C, Grimes J, *et al.*: Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. *J Acquir Immune Defic Syndr* 2000;24(4):316–324.
10. Bersoff-Matcha SJ, Miller WC, Aberg JA, *et al.*: Sex differences in nevirapine rash. *Clin Infect Dis* 2001;32(1):124–129.
11. Nicastrì E, Leone S, Angeletti C, *et al.*: Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review. *J Antimicrob Chemother* 2007;60(4):724–732.
12. Hodder S, Arasteh K, De Wet J, *et al.*: Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. *HIV Med* 2012;13(7):406–415.
13. Barber TJ, Geretti AM, Anderson J, *et al.*: Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. *Antivir Ther* 2011;16(6):805–814.
14. Murri R, Lepri AC, Phillips AN, *et al.*: Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A. Study. *J Acquir Immune Defic Syndr* 2003;34(2):184–190.
15. Currier J, Averitt Bridge D, Hagins D, *et al.*: Sex-based outcomes of darunavir-ritonavir therapy: A single-group trial. *Ann Intern Med* 2010;153(6):349–357.
16. Moore AL, Mocroft A, Madge S, *et al.*: Gender differences in virologic response to treatment in an HIV-positive population: A cohort study. *J Acquir Immune Defic Syndr* 2001;26(2):159–163.
17. Mazhude C, Jones S, Murad S, *et al.*: Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. *AIDS* 2002;16(11):1566–1568.
18. Gandhi M, Aweeka F, Greenblatt RM, *et al.*: Sex differences in pharmacokinetics and pharmacodynamics. *Annu Rev Pharmacol Toxicol* 2004;44:499–523.
19. Siddiqui RA, Sauermann U, Altmüller J, *et al.*: X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. *Am J Hum Genet* 2009;85(2):228–239.
20. Borges AH, O'Connor JL, Phillips AN, *et al.*: Factors associated with D-dimer levels in HIV-infected individuals. *PLoS One* 2014;9(3):e90978.
21. Meier A, Chang JJ, Chan ES, *et al.*: Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. *Nat Med* 2009;15(8):955–959.
22. Sajadi MM, Guan Y, DeVico AL, *et al.*: Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. *J Acquir Immune Defic Syndr* 2011;57(1):9–15.
23. Seillet C, Laffont S, Tremollieres F, *et al.*: The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. *Blood* 2012;119(2):454–464.
24. Chang JJ, Woods M, Lindsay RJ, *et al.*: Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. *J Infect Dis* 2013;208(5):830–838.
25. Fitch KV, Srinivasa S, Abbara S, *et al.*: Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. *J Infect Dis* 2013;208(11):1737–1746.
26. Jantarotnotai N, Utaisincharn P, Sanvarinda P, *et al.*: Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia. *Int Immunopharmacol* 2013;17(2):483–488.
27. Weinberg A, Enomoto L, Marcus R, *et al.*: Effect of menstrual cycle variation in female sex hormones on cellular immunity and regulation. *J Reprod Immunol* 2011;89(1):70–77.
28. Lee YW, Eum SY, Nath A, and Toborek M: Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells. *Cardiovasc Res* 2004;63(1):139–148.
29. Asin SN, Heimberg AM, Eszterhas SK, *et al.*: Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. *AIDS Res Hum Retroviruses* 2008;24(5):701–716.
30. Katagiri D, Hayashi H, Victoriano AF, *et al.*: Estrogen stimulates transcription of human immunodeficiency virus type 1 (HIV-1). *Int Immunopharmacol* 2006;6(2):170–181.
31. Wilson ME, Allred KF, Bisotti AJ, *et al.*: Estradiol negatively regulates HIV-LTR promoter activity in glial cells. *AIDS Res Hum Retroviruses* 2006;22(4):350–356.
32. Heron PM, Turchan-Cholewo J, Bruce-Keller AJ, *et al.*: Estrogen receptor alpha inhibits the estrogen-mediated suppression of HIV transcription in astrocytes: Implications for estrogen neuroprotection in HIV dementia. *AIDS Res Hum Retroviruses* 2009;25(11):1071–1081.
33. Szotek EL, Narasipura SD, and Al-Harthi L: 17beta-Estradiol inhibits HIV-1 by inducing a complex formation between beta-catenin and estrogen receptor alpha on the HIV promoter to suppress HIV transcription. *Virology* 2013;443(2):375–383.
34. Tasker C, Ding J, Schmolke M, *et al.*: 17beta-Estradiol protects primary macrophages against HIV infection through induction of interferon-alpha. *Viral Immunol* 2014;27(4):140–150.
35. Laurence J, Cooke H, and Sikder SK: Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1. *Blood* 1990;75(3):696–703.
36. Pinheiro I, Dejager L, and Libert C: X-chromosome-located microRNAs in immunity: Might they explain male/

- female differences? The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. *Bioessays* 2011;33(11):791–802.
37. Addo MM and Altfeld M: Sex-based differences in HIV type 1 pathogenesis. *J Infect Dis* 2014;209(Suppl 3):S86–S92.
 38. Tran TA, de Goer de Herve MG, Hendel-Chavez H, *et al.*: Resting regulatory CD4 T cells: A site of HIV persistence in patients on long-term effective antiretroviral therapy. *PLoS One* 2008;3(10):e3305.
 39. Arruvito L, Sanz M, Banham AH, *et al.*: Expansion of CD4+ CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: Implications for human reproduction. *J Immunol* 2007;178(4):2572–2578.
 40. Joshua TV, Rizzo JD, Zhang MJ, *et al.*: Access to hematopoietic stem cell transplantation: Effect of race and sex. *Cancer* 2010;116(14):3469–3476.
 41. Mehta P, Pollock BH, Nugent M, *et al.*: Access to stem cell transplantation: Do women fare as well as men? *Am J Hematol* 2003;72(2):99–102.
 42. Grant M, Cooke L, Williams AC, *et al.*: Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: A comparison of sociodemographic, disease, and treatment characteristics. *Support Care Cancer* 2012;20(11):2697–2704.
 43. Gratwohl A, Stern M, Brand R, *et al.*: Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis. *Cancer* 2009;115(20):4715–4726.
 44. Johnny A, Song KW, Nantel SH, *et al.*: Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. *Biol Blood Marrow Transplant* 2006;12(4):480–489.
 45. Deasy BM, Lu A, Tebbets JC, *et al.*: A role for cell sex in stem cell-mediated skeletal muscle regeneration: Female cells have higher muscle regeneration efficiency. *J Cell Biol* 2007;177(1):73–86.
 46. Yukl SA, Boritz E, Busch M, *et al.*: Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. *PLoS Pathog* 2013;9(5):e1003347.
 47. Chun TW, Justement JS, Murray D, *et al.*: Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication. *AIDS* 2010;24(18):2803–2808.
 48. Jain V, Hartogensis W, Bacchetti P, *et al.*: Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. *J Infect Dis* 2013;208(8):1202–1211.
 49. Boulassel MR, Chomont N, Pai NP, *et al.*: CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. *J Clin Virol* 2012;53(1):29–32.
 50. Stengaard AR, Lazarus JV, Donoghoe MC, *et al.*: Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002–2006. *AIDS Care* 2009;21(7):893–902.
 51. WHO, UNICEF, UNAIDS: Global update on HIV treatment 2013: Results, impact and opportunities, 2013.
 52. CDC: HIV in the United States: The Stages of Care. www.cdc.gov/hiv/pdf/research_mmp_stagesofcare.pdf. Accessed July 14, 2014.
 53. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. *Lancet* 2000;355(9210):1131–1137.
 54. Nakagawa F: Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naïve individuals. *AIDS* 2014;28(9):1351–1356.
 55. Allers K, Bosel D, Eppl HJ, *et al.*: Effect of age on the CD4(+) T-cell impairment in HIV-infected persons without and with cART. *J Acquir Immune Defic Syndr* 2014;66(1):7–15.
 56. Althoff KN, Justice AC, Gange SJ, *et al.*: Virologic and immunologic response to HAART, by age and regimen class. *AIDS* 2010;24(16):2469–2479.
 57. Dumond JB, Adams JL, Prince HM, *et al.*: Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: A pilot study. *HIV Med* 2013;14(7):401–409.
 58. Goodkin K, Shapshak P, Asthana D, *et al.*: Older age and plasma viral load in HIV-1 infection. *AIDS* 2004;18(Suppl 1):S87–98.
 59. Greig J, Casas EC, O'Brien DP, *et al.*: Association between older age and adverse outcomes on antiretroviral therapy: A cohort analysis of programme data from nine countries. *AIDS* 2012;26(Suppl 1):S31–37.
 60. Kalayjian RC, Spritzler J, Matining RM, *et al.*: Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. *AIDS* 2013;27(10):1563–1571.
 61. Sabin CA, Smith CJ, d'Arminio Monforte A, *et al.*: Response to combination antiretroviral therapy: Variation by age. *AIDS* 2008;22(12):1463–1473.
 62. Andrade RM, Hygino J, Kasahara TM, *et al.*: High IL-10 production by aged AIDS patients is related to high frequency of Tr-1 phenotype and low in vitro viral replication. *Clin Immunol* 2012;145(1):31–43.
 63. Deeks SG: HIV infection, inflammation, immunosenescence, and aging. *Annu Rev Med* 2011;62:141–155.
 64. Dock JN and Effros RB: Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence. *Aging Dis* 2011;2(5):382–397.
 65. Hoffman RM, Jamieson BD, Bosch RJ, *et al.*: Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals. *J Clin Immunol* 2011;31(5):873–881.
 66. Tassiopoulos K, Landay A, Collier AC, *et al.*: CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naïve HIV-infected adults enrolled in adult clinical trials group studies. *J Infect Dis* 2012;205(11):1730–1738.
 67. Tenorio AR, Spritzler J, Martinson J, *et al.*: The effect of aging on T-regulatory cell frequency in HIV infection. *Clin Immunol* 2009;130(3):298–303.
 68. Gratwohl A, Hermans J, Goldman JM, *et al.*: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Lancet* 1998;352(9134):1087–1092.
 69. Sorror ML, Sandmaier BM, Storer BE, *et al.*: Long-term outcomes among older patients following nonmyeloablative

- conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. *JAMA* 2011; 306(17):1874–1883.
70. Bogunia-Kubik K, Duda D, Suchnicki K, *et al.*: CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Haematologica* 2006;91(12):1628–1634.
 71. Bogunia-Kubik K, Suchnicki K, and Lange A: HLA-DR11 in addition to donor age, gender, and major blood group incompatibility influence the incidence of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Transplant Proc* 2003;35(4): 1556–1558.
 72. Imahashi N, Suzuki R, Fukuda T, *et al.*: Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. *Bone Marrow Transplant* 2013;48(1):56–62.
 73. Althoff KN, Gebo KA, Gange SJ, *et al.*: CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? *AIDS Res Ther* 2010;7:45.
 74. Mocroft A, Lundgren JD, Sabin ML, *et al.*: Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). *PLoS Med* 2013;10(9):e1001510.
 75. Montlahuc C, Guiguet M, Abgrall S, *et al.*: Impact of late presentation on the risk of death among HIV-infected people in France (2003–2009). *J Acquir Immune Defic Syndr* 2013;64(2):197–203.
 76. Smith PR, Sarner L, Murphy M, *et al.*: Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. *J Clin Virol* 2003;26(1):101–107.
 77. Anastos K, Gange SJ, Lau B, *et al.*: Association of race and gender with HIV-1 RNA levels and immunologic progression. *J Acquir Immune Defic Syndr* 2000;24(3): 218–226.
 78. Easterbrook PJ, Farzadegan H, Hoover DR, *et al.*: Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. *AIDS* 1996;10(10):1147–1155.
 79. Chikata T, Carlson JM, Tamura Y, *et al.*: Host-specific adaptation of HIV-1 subtype B in the Japanese population. *J Virol* 2014;88(9):4764–4775.
 80. Gartland AJ, Li S, McNevin J, *et al.*: Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. *J Virol* 2014;88(15):8242–8255.
 81. Murphy K, Hoover DR, Shi Q, *et al.*: Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. *AIDS* 2013;27(15):2413–2423.
 82. Longo DM, Louie B, Mathi K, *et al.*: Racial differences in B cell receptor signaling pathway activation. *J Transl Med* 2012;10:113.
 83. Lucey DR, Hendrix CW, Andrzejewski C, *et al.*: Comparison by race of total serum IgG, IgA, and IgM with CD4+ T-cell counts in North American persons infected with the human immunodeficiency virus type 1. *J Acquir Immune Defic Syndr* 1992;5(4):325–332.
 84. Kalinkovich A, Borkow G, Weisman Z, *et al.*: Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: Environmental and constitutive factors. *Clin Immunol* 2001;100(1):107–117.
 85. Koesters SA, Matu L, Kiama P, *et al.*: Elevation of immune activation in Kenyan women is associated with alterations in immune function: Implications for vaccine development. *J Clin Immunol* 2004;24(6):702–709.
 86. Messele T, Abdulkadir M, Fontanet AL, *et al.*: Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. *Clin Exp Immunol* 1999;115(3):443–450.
 87. Kile DA, MaWhinney S, Aquilante CL, *et al.*: A population pharmacokinetic-pharmacogenetic analysis of atazanavir. *AIDS Res Hum Retroviruses* 2012;28(10):1227–1234.
 88. Li J, Menard V, Benish RL, *et al.*: Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: Implications for HIV/AIDS treatment. *Pharmacogenomics* 2012;13(5):555–570.
 89. Ribaud HJ, Liu H, Schwab M, *et al.*: Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS Clinical Trials Group study. *J Infect Dis* 2010;202(5): 717–722.
 90. de Maat MM, Nellen JF, Huitema AD, *et al.*: Race is not associated with nevirapine pharmacokinetics. *Ther Drug Monit* 2004;26(4):456–458.
 91. Stohr W, Back D, Dunn D, *et al.*: Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. *Antivir Ther* 2008; 13(5):675–685.
 92. Saag M, Balu R, Phillips E, *et al.*: High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. *Clin Infect Dis* 2008;46(7):1111–1118.
 93. Orkin C, Sadiq ST, Rice L, *et al.*: Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. *HIV Med* 2010;11(3):187–192.
 94. Rozenberg L, Haagmans BL, Neumann AU, *et al.*: Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. *AIDS* 2009;23(18):2439–2450.
 95. HIV gp120 vaccine–VaxGen: AIDS-VAX, AIDS-VAX B/ B, AIDS-VAX B/E, HIV gp120 vaccine–Genentech, HIV gp120 vaccine AIDS-VAX–VaxGen, HIV vaccine AIDS-VAX–VaxGen. *Drugs R D* 2003;4(4):249–253.
 96. Mielcarek M, Gooley T, Martin PJ, *et al.*: Effects of race on survival after stem cell transplantation. *Biol Blood Marrow Transplant* 2005;11(3):231–239.
 97. Roeder C, Jordan S, Schulze Zur Wiesch J, *et al.*: Age-related differences in response to peginterferon alfa-2a/ ribavirin in patients with chronic hepatitis C infection. *World J Gastroenterol* 2014;20(31):10984–10993.
 98. Malnick S, Maor Y, Melzer E, *et al.*: Chronic hepatitis C in the aged: Much ado about nothing or nothing to do? *Drugs Aging* 2014;31(5):339–347.
 99. Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, *et al.*: Gender influence on treatment of chronic hepatitis C genotype 1. *Rev Soc Bras Med Trop* 2010;43(3):217–223.
 100. Giannelli V, Giusto M, Farcomeni A, *et al.*: Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. *Transpl Int* 2012;25(4): 448–454.
 101. Lawitz E, Mangia A, Wyles D, *et al.*: Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* 2013;368(20):1878–1887.

102. NIH: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, amended, October 2001. http://grants1.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.ht. Accessed June 26, 2014.
103. Clayton JA and Collins FS: Policy: NIH to balance sex in cell and animal studies. *Nature* 2014;509(7500):282–283.
104. CDC: Epidemiology of HIV Infection through 2011. www.cdc.gov/hiv/pdf/statistics_epidemiology_of_infection_through_2011.pdf. Accessed June 26, 2014.
105. CDC: HIV Among Older Americans. www.cdc.gov/hiv/risk/age/olderamericans/. Accessed June 26, 2014.
106. UNAIDS: Women, Girls, Gender Equality and HIV. www.unaids.org/en/media/unaids/contentassets/documents/factsheet/2012/20120217_FS_WomenGirls_en.pdf. Accessed June 26, 2014.
107. UNAIDS: HIV and Aging: A special supplement to the UNAIDS report on the global AIDS epidemic 2013. www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/20131101_JC2563_hiv-and-aging_en.pdf. Accessed June 26, 2014.
108. UNAIDS: Core Epidemiology Slides; September 2013. www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/201309_epi_core_en.pdf. Accessed June 26, 2014.
109. Falcon R, Bridge DA, Currier J, *et al.*: Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the gender, race and clinical experience study. *J Womens Health (Larchmt)* 2011;20(7):1043–1050.
110. Desquilbet L, Goujard C, Rouzioux C, *et al.*: Does transient HAART during primary HIV-1 infection lower the virological set-point? *AIDS* 2004;18(18):2361–2369.
111. Hoen B, Fournier I, Lacabartz C, *et al.*: Structured treatment interruptions in primary HIV-1 infection: The ANRS 100 PRIMSTOP trial. *J Acquir Immune Defic Syndr* 2005;40(3):307–316.
112. McKellar MS, Cope AB, Gay CL, *et al.*: Acute HIV-1 infection in the Southeastern United States: A cohort study. *AIDS Res Hum Retroviruses* 2013;29(1):121–128.
113. 2012 HIV/STD Surveillance Report: <http://epi.publichealth.nc.gov/cd/stds/figures/std12rpt.pdf>. Accessed September 9, 2014.
114. Hecht FM: Personal communication. UCSF School of Medicine.
115. San Francisco AIDS Foundation: <http://sfaf.org/hiv-info/statistics/>. Accessed September 10, 2014.
116. Sabundayo BP, McArthur JH, Langan SJ, *et al.*: High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. *Pharmacotherapy* 2006;26(5):674–681.
117. Maryland Department of Health and Mental Hygiene: <http://phpa.dhmm.maryland.gov/OIDEOR/CHSE/SitePages/statistics.aspx>. Accessed September 10, 2014.
118. Krastinova E, Seng R, Yeni P, *et al.*: Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. *PLoS One* 2013;8(8):e71473.
119. AVERT: www.avert.org/european-hiv-aids-statistics.htm. Accessed September 10, 2014.
120. Fidler S, Porter K, Ewings F, *et al.*: Short-course antiretroviral therapy in primary HIV infection. *N Engl J Med* 2013;368(3):207–217.
121. Castillo-Mancilla JR, Cohn SE, Krishnan S, *et al.*: Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials. *HIV Clin Trials* 2014;15(1):14–26.
122. Soon GG, Min M, Struble KA, *et al.*: Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008). *AIDS Patient Care STDS* 2012;26(8):444–453.
123. Manfredi R: HIV disease and advanced age: An increasing therapeutic challenge. *Drugs Aging* 2002;19(9):647–669.
124. Dhalla S and Poole G: Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. *Hum Vaccin Immunother* 2014;10(7).
125. Byrd GS, Edwards CL, Kelkar VA, *et al.*: Recruiting intergenerational African American males for biomedical research Studies: A major research challenge. *J Natl Med Assoc* 2011;103(6):480–487.
126. Metch B, Frank I, Novak R, *et al.*: Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. *AIDS Behav* 2013;17(2):760–772.
127. Blackstock OJ, Beach MC, Korthuis PT, *et al.*: HIV providers' perceptions of and attitudes toward female versus male patients. *AIDS Patient Care STDS* 2012;26(10):582–588.
128. van Ryn M, Burgess D, Malat J, *et al.*: Physicians' perceptions of patients' social and behavioral characteristics and race disparities in treatment recommendations for men with coronary artery disease. *Am J Public Health* 2006;96(2):351–357.
129. Steward WT, Koester KA, Myers JJ, *et al.*: Provider fatalism reduces the likelihood of HIV-prevention counseling in primary care settings. *AIDS Behav* 2006;10(1):3–12.
130. Martinson JJ, Chapman NH, Rees DC, *et al.*: Global distribution of the CCR5 gene 32-basepair deletion. *Nat Genet* 1997;16(1):100–103.
131. Jakobsson M, Scholz SW, Scheet P, *et al.*: Genotype, haplotype and copy-number variation in worldwide human populations. *Nature* 2008;451(7181):998–1003.

Address correspondence to:

Rowena E. Johnston

amfAR, The Foundation for AIDS Research
120 Wall Street, 13th Floor
New York, New York 10005

E-mail: Rowena.johnston@amfar.org